Brief Description
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 12 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Estimated Enrollment
466
Estimated End Date
2027
Trial is for people with
Key Inclusion Criteria: • APOL1 genotype assessed during screening, participants must have of G1/G1, G2/G2, or G1/G2 • ...
About the drug or intervention
The AMPLITUDE clinical research study is exploring an investigational study drug called VX-147 to learn more about how well it works ...
Find other locations for this trial:
Kinston, NC (Eastern Nephrology Associates- Kinston Office)